Participating Faculty

Supplements and Featured Publications, New Perspectives on Overactive Bladder and Its Treatment, Volume 15, Issue 4

This supplement to The American Journal of Managed Care provides information on overactive bladder (OAB).

OAB is a common chronic urological condition affecting over 33 million men and women in the United States. Recent studies show that OAB can impair work productivity, and the total economic impact is estimated to be more than $25 billion annually.

Participating Faculty

Tamara Bavendam, MD

Senior Medical Director

Pfizer Inc

New York, New York

Sandra J. Berriman, PhD

Medical Director

Pfizer Inc

New York, New York

Marina Brodsky, PhD

Medicines Team Leader

Pfizer Inc

New York, New York

Linda Brubaker, MD

Professor of Obstetrics/Gynecology and Urology

Departments of Obstetrics & Gynecology and Urology

Loyola University

Chicago, Illinois

J. Quentin Clemens, MD, MSCI

Associate Professor

Department of Urology

University of Michigan

Ann Arbor, Michigan

Karin S. Coyne, PhD, MPH

Senior Research Leader

Center for Health Outcomes Research

United BioSource Corporation

Bethesda, Maryland

Pamela Ellsworth, MD

Associate Professor of Urology

Brown University

Providence, Rhode Island

Erica L. Goldberg

Senior Consultant

IMS Health, Inc.

Falls Church, Virginia

Debra E. Irwin, MSPH, PhD

Research Assistant Professor

Department of Epidemiology

University of North Carolina

Chapel Hill, North Carolina

Zoe S. Kopp, PhD, MPH

Senior Director, Outcomes Research

Pfizer Inc

New York, New York

Diane McNally, BSPharm, MS

Research Manager

Department of Pharmaceutical Health Services Research

School of Pharmacy

University of Maryland

Baltimore, Maryland

C. Daniel Mullins, PhD

Professor

Department of Pharmaceutical Health Services Research

School of Pharmacy

University of Maryland

Baltimore, Maryland

Ebere Onukwugha, PhD

Assistant Professor

Department of Pharmaceutical Health Services Research

School of Pharmacy

University of Maryland

Baltimore, Maryland

Elise M. Pelletier, MS

Director, Health Economics and Outcomes Research

IMS Health, Inc.

Watertown, Massachusetts

Vernon F. Schabert, PhD

Senior Director, Health Economics and Outcomes Research

IMS Health, Inc.

Falls Church, Virginia

Chris C. Sexton, PhD

Senior Research Associate

Center for Health Outcomes Research

United BioSource Corporation

Bethesda, Maryland

Jeffrey N. Trocio, MPH

Manager, Global Outcomes Research

Pfizer Inc.

New York, New York

Vasudha Vats, MPH

Manager, Global Outcomes Research

Pfizer Inc

New York, New York

Todd H. Wagner, PhD

Health Economist

Department of Veterans Affairs

Health Economics Resource Center

Menlo Park, California

Ilene H. Zuckerman, PharmD, PhD

Professor

Department of Pharmaceutical Health Services Research

School of Pharmacy

University of Maryland

Baltimore, Maryland

Faculty Disclosures

Tamara Bavendam, MD

Employee: Pfizer Inc

Sandra J. Berriman, PhD

Employee: Pfizer Inc

Marina Brodsky, PhD

Employee: Pfizer Inc

Linda Brubaker, MD

Consultant: Pfizer IncResearch Grant: Allergan, Pfizer Inc

J. Quentin Clemens, MD, MSCI

Lecturer: Pfizer Inc

Karin S. Coyne, PhD, MPH

Consultant: Pfizer Inc

Pamela Ellsworth, MD

Consultant: Allergan, Novartis, Pfizer IncHonoraria: Allergan, NovartisLecturer: Allergan, Novartis

Erica L. Goldberg

Research Grant: Pfizer Inc

Debra E. Irwin, MSPH, PhD

Consultant: Pfizer Inc

Zoe S. Kopp, PhD, MPH

Employee: Pfizer Inc

C. Daniel Mullins, PhD

Consultant: Novartis, Pfizer IncGrants: Pfizer IncHonoraria: Pfizer Inc

Ebere Onukwugha, PhD

Consultant: Pfizer IncGrants: Pfizer Inc

Elise M. Pelletier, MS

Consultant: Pfizer Inc

Vernon F. Schabert, PhD

Research Grant: Pfizer Inc

Chris C. Sexton, PhD

Consultant: Pfizer Inc

Jeffrey N. Trocio, MPH

Employee: Pfizer Inc

Vasudha Vats, MPH

Employee: Pfizer Inc

Diane McNally, BSPharm, MS, Todd H. Wagner, PhD

Ilene H. Zuckerman, PharmD, PhD

, and , have no conflicts to disclose.

The contents of this supplement may include information regarding the use of products that may be inconsistent with or outside the approved labeling for these products in the United States. Physicians should note that the use of these products outside current approved labeling is considered experimental and are advised to consult prescribing information for these products.

Pfizer Inc.

This supplement was funded by